Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
71
EWTX Quote, Financials, Valuation and Earnings
Last price:
$26.36
Seasonality move
:
-4%
Day range:
$25.36 - $27.39
52-week range:
$10.60 - $30.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.99x
Volume:
2.4M
Avg. volume:
1.8M
1-year change:
-11.16%
Market cap:
$2.8B
Revenue:
--
EPS (TTM):
-$1.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
-- | -$0.46 | -- | -6.04% | $38.17 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.6M | -$1.88 | 12.2% | -14.88% | $36.00 |
|
DVAX
Dynavax Technologies Corp.
|
$84.7M | -$0.02 | 11.43% | 73.54% | $20.50 |
|
GILD
Gilead Sciences, Inc.
|
$7B | $2.03 | 1.49% | 33.42% | $132.38 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OMER
Omeros Corp.
|
-- | -$0.48 | -- | -0.15% | $28.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
$26.35 | $38.17 | $2.8B | -- | $0.00 | 0% | -- |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$28.02 | $36.00 | $1.6B | 3.91x | $0.00 | 0% | 36.08x |
|
DVAX
Dynavax Technologies Corp.
|
$15.38 | $20.50 | $1.8B | 54.00x | $0.00 | 0% | 6.43x |
|
GILD
Gilead Sciences, Inc.
|
$124.70 | $132.38 | $154.7B | 19.31x | $0.79 | 2.53% | 5.39x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
OMER
Omeros Corp.
|
$15.71 | $28.00 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
0.74% | 1.363 | 0.24% | 26.03x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.35% | 3.272 | 1.9% | 12.81x |
|
DVAX
Dynavax Technologies Corp.
|
35.13% | -0.293 | 24.82% | 6.74x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OMER
Omeros Corp.
|
254.22% | -1.203 | 126.5% | 0.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics, Inc.
|
-$570K | -$46.9M | -30.86% | -31.13% | -- | -$34.9M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$9.8M | -$116.9M | -26.57% | -27.53% | -907.37% | -$89.7M |
|
DVAX
Dynavax Technologies Corp.
|
$80.5M | $21.3M | -5.15% | -7.65% | 22.42% | $32.6M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
Edgewise Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns EWTX or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of -803.05%. Edgewise Therapeutics, Inc.'s return on equity of -31.13% beat Agios Pharmaceuticals, Inc.'s return on equity of -27.53%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B -
What do Analysts Say About EWTX or AGIO?
Edgewise Therapeutics, Inc. has a consensus price target of $38.17, signalling upside risk potential of 44.85%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 28.48%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Edgewise Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is EWTX or AGIO More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.867, suggesting its less volatile than the S&P 500 by 13.282%.
-
Which is a Better Dividend Stock EWTX or AGIO?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or AGIO?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $12.9M. Edgewise Therapeutics, Inc.'s net income of -$40.7M is higher than Agios Pharmaceuticals, Inc.'s net income of -$103.4M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 36.08x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M AGIOAgios Pharmaceuticals, Inc.36.08x 3.91x $12.9M -$103.4M
-
Which has Higher Returns EWTX or DVAX?
Dynavax Technologies Corp. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of 28.38%. Edgewise Therapeutics, Inc.'s return on equity of -31.13% beat Dynavax Technologies Corp.'s return on equity of -7.65%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M -
What do Analysts Say About EWTX or DVAX?
Edgewise Therapeutics, Inc. has a consensus price target of $38.17, signalling upside risk potential of 44.85%. On the other hand Dynavax Technologies Corp. has an analysts' consensus of $20.50 which suggests that it could grow by 33.29%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Edgewise Therapeutics, Inc. is more attractive than Dynavax Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 DVAXDynavax Technologies Corp.1 1 1 -
Is EWTX or DVAX More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dynavax Technologies Corp. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.
-
Which is a Better Dividend Stock EWTX or DVAX?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dynavax Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Dynavax Technologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or DVAX?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Dynavax Technologies Corp. quarterly revenues of $94.9M. Edgewise Therapeutics, Inc.'s net income of -$40.7M is lower than Dynavax Technologies Corp.'s net income of $26.9M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Dynavax Technologies Corp.'s PE ratio is 54.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 6.43x for Dynavax Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M DVAXDynavax Technologies Corp.6.43x 54.00x $94.9M $26.9M
-
Which has Higher Returns EWTX or GILD?
Gilead Sciences, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of 39.21%. Edgewise Therapeutics, Inc.'s return on equity of -31.13% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About EWTX or GILD?
Edgewise Therapeutics, Inc. has a consensus price target of $38.17, signalling upside risk potential of 44.85%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.16%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Edgewise Therapeutics, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 GILDGilead Sciences, Inc.16 8 0 -
Is EWTX or GILD More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock EWTX or GILD?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.79 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or GILD?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Edgewise Therapeutics, Inc.'s net income of -$40.7M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 5.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M GILDGilead Sciences, Inc.5.39x 19.31x $7.8B $3.1B
-
Which has Higher Returns EWTX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of -255.85%. Edgewise Therapeutics, Inc.'s return on equity of -31.13% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About EWTX or NBY?
Edgewise Therapeutics, Inc. has a consensus price target of $38.17, signalling upside risk potential of 44.85%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Edgewise Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Edgewise Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is EWTX or NBY More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock EWTX or NBY?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or NBY?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Edgewise Therapeutics, Inc.'s net income of -$40.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns EWTX or OMER?
Omeros Corp. has a net margin of -- compared to Edgewise Therapeutics, Inc.'s net margin of --. Edgewise Therapeutics, Inc.'s return on equity of -31.13% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EWTXEdgewise Therapeutics, Inc.-- -$0.39 $562.8M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About EWTX or OMER?
Edgewise Therapeutics, Inc. has a consensus price target of $38.17, signalling upside risk potential of 44.85%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 78.23%. Given that Omeros Corp. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Edgewise Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EWTXEdgewise Therapeutics, Inc.7 2 0 OMEROmeros Corp.2 2 0 -
Is EWTX or OMER More Risky?
Edgewise Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.
-
Which is a Better Dividend Stock EWTX or OMER?
Edgewise Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edgewise Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EWTX or OMER?
Edgewise Therapeutics, Inc. quarterly revenues are --, which are smaller than Omeros Corp. quarterly revenues of --. Edgewise Therapeutics, Inc.'s net income of -$40.7M is lower than Omeros Corp.'s net income of -$21.2M. Notably, Edgewise Therapeutics, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edgewise Therapeutics, Inc. is -- versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EWTXEdgewise Therapeutics, Inc.-- -- -- -$40.7M OMEROmeros Corp.-- -- -- -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
